Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Selective Histone Deacetylase Inhibitors

Author(s): Huili Pan, Jiangying Cao and Wenfang Xu

Volume 12, Issue 3, 2012

Page: [247 - 270] Pages: 24

DOI: 10.2174/187152012800228814

Price: $65

Abstract

Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.

Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy